NCT05908409 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
| NCT ID | NCT05908409 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | IDP Discovery Pharma S.L. |
| Condition | Multiple Myeloma (MM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 37 participants |
| Start Date | 2023-06-05 |
| Primary Completion | 2025-12-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 37 participants in total. It began in 2023-06-05 with a primary completion date of 2025-12-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). * Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years 2. Performance status (ECOG) ≤ 2 3. Life expectancy ≥3 months 4. Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements. 5. Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. 6. Patients diagnosed with chronic lymphocytic leukemia (CLL), B-cell lymphomas, and multiple myeloma (MM) who are ineligible to reveive the available treatments. 7. Adequate hematological or biochemical parameters as specified below 1. Hemoglobin \> 8.0 g/dl (without transfusion support within 7 days) 2. Platelets count \> 75 x109/L (without transfusional support within 7 days). In patients with bone marrow infiltration, the platelets count may be ≥50 x109/L. 3. Absolute neutrophil count (ANC) \> 0.75 x109/L (without G-CSF support within 7 days) 4. Aspartate transaminase (AST): \<2.5 x the upper limit range (in patients with no liver metastases or \<5 x ULN in patients with liver metastases) 5. Alanine transaminase (ALT): \< 2.5 x the upper limit range (in patients with no liver metastases or \<5 x ULN in patients with liver metastases) 6. Total bilirubin: \< 2 x the upper limit range. 7. Calculated or measured creatinine clearance: \>30 mL/min (calculated from the Cockcroft-Gault formula). 8. Left ventricular ejection fraction \> 50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram. Exclusion Criteria: 1. Persistent clinically significant non-hematological toxicity related to previous treatments. The presence of alopecia and NCI-CTC grade \<2 symptomatic peripheral neuropathy is allowed. 2. Pregnant or lactating women; men and women of reproductive potential\* (as defined in the Appendix 2) who are not using effective contraceptive methods (combined hormonal contraception associated with inhibition of ovulation; progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinenence). \*A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy. 3. History of any other neoplastic disease in the last five years (except basal cell carcinoma, skin epithelioma or carcinoma in situ of any site) 4. History of clinically significant hypotension. 5. History of clinically significant allergic or hyper-sensitivity reactions. 6. History or known clinically significant vascular disease or known high risk of vascular disease (as assessed by the treating physician) including (but not limited to): * Thromboembolism * Peripheral arterial disease * Vasculitis 7. Other relevant diseases or adverse clinical conditions: * Congestive heart failure or angina pectoris, myocardial infarction within 12 months before inclusion in the study. * Uncontrolled arterial hypertension or cardiac arrhythmias (i.e., requiring a change in medication within the last 3 months or hospital admission within the past 6 months). * History of significant neurological or psychiatric disorders 8. Clinically significant or active infection. 9. Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis) 10. The patient is known to be human immunodeficiency virus (HIV) positive, unless the patient is on antiviral therapy with HIV RNA levels \<50 copies/mL; Hepatitis B surface antigen-positive or active hepatitis C infection, unless treated with undetectable hepatitis B DNA or hepatitis C RNA levels; or active CMV infection (IgM positive). 11. Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle 1. 12. Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunosuppressive treatment 13. Limitation of the patient's ability to comply with the treatment or follow-up protocol. 14. If a COVID-19 vaccine is administered, it should be done \>72 hours prior to study treatment initiation or after the completion of the dose-limiting toxicity (DLT) period (if patient is participating in the dose-escalation phase").
Contact & Investigator
Enrique Ocio San Miguel, MD, PhD
PRINCIPAL INVESTIGATOR
Hospital Universitario Marqués de Valdecilla
Frequently Asked Questions
Who can join the NCT05908409 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma (MM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05908409 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05908409 currently recruiting?
Yes, NCT05908409 is actively recruiting participants. Contact the research team at d.molina@idp-pharma.com for enrollment information.
Where is the NCT05908409 trial being conducted?
This trial is being conducted at Santander, Spain, Salamanca, Spain, Barcelona, Spain, Barcelona, Spain and 7 additional locations.
Who is sponsoring the NCT05908409 clinical trial?
NCT05908409 is sponsored by IDP Discovery Pharma S.L.. The principal investigator is Enrique Ocio San Miguel, MD, PhD at Hospital Universitario Marqués de Valdecilla. The trial plans to enroll 37 participants.